Skip to main content

Articles

Page 28 of 31

  1. Fluid biomarkers improve the diagnostic accuracy in dementia and provide an objective measure potentially useful as a therapeutic response in clinical trials. The role of fluid biomarkers in patient care is a ...

    Authors: Pedro Rosa-Neto, Ging-Yuek Robin Hsiung and Mario Masellis
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S8
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  2. Recently published guidelines suggest that the most opportune time to treat individuals with Alzheimer’s disease is during the preclinical phase of the disease. This is a phase when individuals are defined as ...

    Authors: Dorene M Rentz, Mario A Parra Rodriguez, Rebecca Amariglio, Yaakov Stern, Reisa Sperling and Steven Ferris
    Citation: Alzheimer's Research & Therapy 2013 5:58
    Content type: Review Published on:

  5. The clinical features of Alzheimer’s disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable ...

    Authors: Noemí Esteras, Carolina Alquézar, Ana de la Encarnación, Alberto Villarejo, Félix Bermejo-Pareja and Ángeles Martín-Requero
    Citation: Alzheimer's Research & Therapy 2013 5:55
    Content type: Research Published on:

  7. Autophagy serves as the sole catabolic mechanism for degrading organelles and protein aggregates. Increasing evidence implicates autophagic dysfunction in Alzheimer’s disease (AD) and other neurodegenerative d...

    Authors: Miranda E Orr and Salvatore Oddo
    Citation: Alzheimer's Research & Therapy 2013 5:53
    Content type: Review Published on:

  8. The aim of this study was to explore the predictors of decline in walking ability in patients with Alzheimer’s disease (AD).

    Authors: Yves Rolland, Christelle Cantet, Philipede Souto Barreto, Matteo Cesari, Gabor Abellan van Kan and Bruno Vellas
    Citation: Alzheimer's Research & Therapy 2013 5:52
    Content type: Research Published on:

  9. Intraparenchymal injections of the immunotoxin 192-IgG-saporin into medial septum and nucleus basalis magnocellularis causes a selective depletion of basal forebrain cholinergic neurons. Thus, it represents a ...

    Authors: Debora Cutuli, Paola De Bartolo, Paola Caporali, Anna Maria Tartaglione, Diego Oddi, Francesca Romana D’Amato, Annalisa Nobili, Marcello D’Amelio and Laura Petrosini
    Citation: Alzheimer's Research & Therapy 2013 5:50
    Content type: Research Published on:

  10. Accumulation and aggregation of the microtubule-associated protein tau are a pathological hallmark of neurodegenerative disorders such as Alzheimer’s disease (AD). In AD, tau becomes abnormally phosphorylated ...

    Authors: Amy M Pooler, Manuela Polydoro, Susanne Wegmann, Samantha B Nicholls, Tara L Spires-Jones and Bradley T Hyman
    Citation: Alzheimer's Research & Therapy 2013 5:49
    Content type: Review Published on:

  11. The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer’s disease (AD). Its primary aims are to investigate the tempora...

    Authors: Krista L Moulder, B Joy Snider, Susan L Mills, Virginia D Buckles, Anna M Santacruz, Randall J Bateman and John C Morris
    Citation: Alzheimer's Research & Therapy 2013 5:48
    Content type: Review Published on:

  12. The neuronal loss in Alzheimer disease (AD) has been described to affect grey matter in the cerebral cortex. However, in the elderly, AD pathology is likely to occur together with subcortical axonal degenerati...

    Authors: Tobias Skillbäck, Henrik Zetterberg, Kaj Blennow and Niklas Mattsson
    Citation: Alzheimer's Research & Therapy 2013 5:47
    Content type: Research Published on:

  14. Knowledge of longitudinal progression in mild Alzheimer’s disease (AD) is required for the evaluation of disease-modifying therapies. Our aim was to observe the effects of long-term cholinesterase inhibitor (C...

    Authors: Carina Wattmo, Åsa K Wallin and Lennart Minthon
    Citation: Alzheimer's Research & Therapy 2013 5:44
    Content type: Research Published on:

  15. Increased knowledge of the biology of synaptic function has led to the development of novel cognitive-enhancing therapeutic strategies with the potential for increased efficacy and safety. This editorial highl...

    Authors: Diana W Shineman, Aaron J Carman, Penny A Dacks, Rachel F Lane and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2013 5:45
    Content type: Editorial Published on:

  20. APOE, which encodes apolipoprotein E, is the most prevalent and best established genetic risk factor for late-onset Alzheimer’s disease. Current understanding of Alzheimer’s disease pathophysiology posits an impo...

    Authors: Andrew B Wolf, Jon Valla, Guojun Bu, Jungsu Kim, Mary Jo LaDu, Eric M Reiman and Richard J Caselli
    Citation: Alzheimer's Research & Therapy 2013 5:38
    Content type: Review Published on:

  22. The possibility to map amyloid-beta, the Alzheimer’s disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid b...

    Authors: Rik Ossenkoppele, Niels D Prins and Bart NM van Berckel
    Citation: Alzheimer's Research & Therapy 2013 5:36
    Content type: Commentary Published on:

  24. Cognitive impairments, and particularly memory deficits, are a defining feature of the early stages of Alzheimer's disease and vascular dementia. Interventions that target these cognitive deficits and the asso...

    Authors: Alex Bahar-Fuchs, Linda Clare and Bob Woods
    Citation: Alzheimer's Research & Therapy 2013 5:35
    Content type: Review Published on:

  25. This paper summarizes the body of literature about early-onset dementia (EOD) that led to recommendations from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. A broader dif...

    Authors: Mario Masellis, Kayla Sherborn, Pedro Rosa Neto, Dessa A Sadovnick, Ging-Yuek R Hsiung, Sandra E Black, Sadhana Prasad, Meghan Williams and Serge Gauthier
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S7
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  27. Alzheimer's disease (AD) is a common neurodegenerative disease characterized by the accumulation of extracellular plaques and intracellular tangles. Recent studies support the hypothesis that the accumulation ...

    Authors: Kristin R Wildsmith, Monica Holley, Julie C Savage, Rebecca Skerrett and Gary E Landreth
    Citation: Alzheimer's Research & Therapy 2013 5:33
    Content type: Review Published on:

  29. The growing population of persons with dementia in Canada and the provision of quality care for this population is an issue that no healthcare authority will escape. Physicians often view dementia as a difficu...

    Authors: Cheryl Cook and Kenneth Rockwood
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S6
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  30. While there have been no new medications approved for the treatment of Alzheimer's disease (AD) or other dementias in Canada since 2004, the Canadian Consensus Conference on the Diagnosis and Treatment of Deme...

    Authors: Nathan Herrmann, Krista L Lanctôt and David B Hogan
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S5
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  31. The Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) was held 3 to 4 May 2012 in Montreal, Quebec, Canada. A group of neuroimaging experts were assigned the task of rev...

    Authors: Amer M Burhan, Robert Bartha, Christian Bocti, Michael Borrie, Robert Laforce Jr, Pedro Rosa-Neto and Jean-Paul Soucy
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S4
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  32. In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and...

    Authors: Jean-Paul Soucy, Robert Bartha, Christian Bocti, Michael Borrie, Amer M Burhan, Robert Laforce Jr and Pedro Rosa-Neto
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S3
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  33. There have been several newly proposed sets of diagnostic criteria for Alzheimer's disease/mild cognitive impairment, advanced by the National Institute of Aging/Alzheimer's Association working groups in 2011 ...

    Authors: Howard Chertkow, Howard H Feldman, Claudia Jacova and Fadi Massoud
    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S2
    Content type: Review Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  36. Advances in the field of blood biomarker discovery will help in identifying Alzheimer's disease in its preclinical stage, allowing treatment to be initiated before irreversible damage occurs. This review discu...

    Authors: Veer Bala Gupta, Ramani Sundaram and Ralph N Martins
    Citation: Alzheimer's Research & Therapy 2013 5:31
    Content type: Review Published on:

  37. In a symposium held at the Clinical Trials in Alzheimer's Disease conference in Monte Carlo, Monaco (29 to 31 October 2012) three different, not mutually exclusive approaches to improve and facilitate clinical...

    Authors: René Spiegel, Rachelle S Doody, Suzanne Hendrix and Kristin Kahle-Wrobleski
    Citation: Alzheimer's Research & Therapy 2013 5:29
    Content type: Viewpoint Published on:

  38. Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may diffe...

    Authors: Laura E Donovan, Eric B Dammer, Duc M Duong, John J Hanfelt, Allan I Levey, Nicholas T Seyfried and James J Lah
    Citation: Alzheimer's Research & Therapy 2013 5:32
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:102

  41. Despite the extensive mechanistic and pathological characterization of the amyloid precursor protein (APP)/presenilin-1 (PS-1) knock-in mouse model of Alzheimer's disease (AD), very little is known about the A...

    Authors: Scott J Webster, Adam D Bachstetter and Linda J Van Eldik
    Citation: Alzheimer's Research & Therapy 2013 5:28
    Content type: Research Published on:

  43. Addressing causes of heterogeneity in cognitive outcomes is becoming more critical as Alzheimer's disease (AD) research focuses on earlier disease. One of the causes of this heterogeneity may be that individua...

    Authors: Suzanne B Hendrix and Kathleen A Welsh-Bohmer
    Citation: Alzheimer's Research & Therapy 2013 5:22
    Content type: Commentary Published on:

  44. Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has ge...

    Authors: Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta and David Schubert
    Citation: Alzheimer's Research & Therapy 2013 5:25
    Content type: Research Published on:

  46. Alzheimer's disease (AD), for which there is no cure, is the most common form of dementia in the elderly. Despite tremendous efforts by the scientific community, the AD drug development pipeline remains extrem...

    Authors: Laurent Lecanu and Vassilios Papadopoulos
    Citation: Alzheimer's Research & Therapy 2013 5:17
    Content type: Review Published on:

  47. The Alzheimer's disease (AD) epidemic is a looming crisis, with an urgent need for new therapies to delay or prevent symptom onset and progression. There is growing awareness that clinical trials must target s...

    Authors: Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker and Allan I Levey
    Citation: Alzheimer's Research & Therapy 2013 5:21
    Content type: Review Published on:

  48. During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition. Several studies with structurally different compounds have shown that not only...

    Authors: María Javier Ramírez
    Citation: Alzheimer's Research & Therapy 2013 5:15
    Content type: Review Published on:

  50. Modulation of the gamma-secretase enzyme, which reduces the production of the amyloidogenic Aβ42 peptide while sparing the production of other Aβ species, is a promising therapeutic approach for the treatment of ...

    Authors: Robyn M Loureiro, Jo Ann Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk and Barbara Tate
    Citation: Alzheimer's Research & Therapy 2013 5:19
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193